Latest Healthcare News

Nanosonics Limited reported a 9% revenue increase in the first half of FY26, driven by a growing installed base and recurring sales, while advancing the commercial rollout of its new CORIS endoscope reprocessing system.

Singular Health Group reported a 55% rise in net loss to $2.97 million for H1 FY2026, driven by share-based payments and strategic hires, while making significant progress in US commercial deployments and securing FDA clearance for its cloud-based 3D medical imaging platform.

Apiam Animal Health has officially become a wholly owned subsidiary of Adamantem Capital's entities following a scheme of arrangement, with shareholders receiving a special dividend and a mix of cash and shares. The company will soon be delisted from the ASX.

Lumos Diagnostics has hit a key enrollment milestone in its BARDA-funded paediatric study for FebriDx®, unlocking a US$720,000 payment and edging closer to FDA expansion.

Neurotech International has reported positive long-term safety results for its lead drug candidate NTI164, bolstering its path towards regulatory approval and chronic use in paediatric neurological disorders.

Argent BioPharma has completed its largest commercial shipment of CannEpil® to Ireland, marking a key milestone in its European expansion with a delivery valued at approximately AUD 783,000. The product is fully reimbursed under Ireland’s National Health Insurance scheme, enhancing patient access for refractory epilepsy treatment.

Mayne Pharma has announced a planned leadership transition with CFO Aaron Gray stepping up as CEO, succeeding Shawn Patrick O’Brien who will remain as an advisor during the handover.

A recent expert panel convened by Novitas has strongly endorsed Pacific Edge’s urine-based Cxbladder tests for hematuria evaluation, recommending Medicare coverage based on robust clinical evidence and patient care benefits.

EMVision Medical Devices reported a $3.97 million loss for H1 2026, up 11% year-on-year, driven by increased share-based payments and expanded clinical activities. The company secured a $3 million government grant to advance stroke diagnosis in regional Australia.

Clarity Pharmaceuticals reports another metastatic prostate cancer patient achieving undetectable disease markers in its Phase II SECuRE trial, reinforcing promising efficacy and safety of its Cu-SAR-bisPSMA radiopharmaceutical.

Regis Healthcare reported a strong 18.4% revenue increase to $667.7 million for H1 2026, despite a 44.8% drop in statutory net profit. The company expanded its aged care portfolio through key acquisitions and declared a fully franked interim dividend.

Pharmx Technologies has entered a multi-year strategic alliance with Sigma Healthcare, becoming the preferred EDI provider for Sigma and Chemist Warehouse across Australia and New Zealand, while Sigma takes a significant equity stake.